Optimizing assisted reproduction: impact of low-dose gonadotropin-releasing hormone agonist on in vitro fertilization outcome.
A novel method of assessing factors that could benefit in vitro fertilization outcome is illustrated by comparison of a low (250 microg) with a standard (500 microg) dose of gonadotropin-releasing hormone agonist, revealing a small decrease in cancellation rates.
Lenton
Elizabeth
E
Sheffield Fertility Centre, Sheffield, United Kingdom. ivf@lento.plus.com
Mohamed
Kamel
K
D002064:Buserelin / Q000008:administration & dosage*; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage*; D005307:Fertilization in Vitro / Q000379:methods* / Q000592:standards; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006728:Hormones / Q000008:administration & dosage; D006801:Humans; D008485:Medical Audit; D011247:Pregnancy; D011256:Pregnancy Outcome
D005300:Fertility Agents, Female; D006728:Hormones; D007987:Gonadotropin-Releasing Hormone; D005640:Follicle Stimulating Hormone; D002064:Buserelin